Health ministry takes steps to boost compliance as corruption cases surface


In the wake of recent controversies surrounding the Central Drugs Standards Control Organisation (CDSCO), the Union is learnt to have been taking steps to improve compliance and crack down on corruption.

Sources in the know said that an internal e-mail was circulated among CDSCO officials earlier this week which explicitly stated that a no tolerance policy would be followed in cases of corruption. “The surveillance mechanism too, is being revamped – including regular close-circuit television monitoring, visitors register monitoring etc,” the source said.

In its FIR, the had stated that Dinesh Dua, director, Synergy Network had met Joint Drugs Controller Eswara Reddy on June 15 in his office in connection with approval of Biocon Biologics files, and later in the day it was approved by the subject expert committee.

The CDSCO thus plans to monitor visitors to any of its officials closely, and avoid any casual visits.

Meanwhile, the Centre has decided to introduce QR codes for ensuring authenticity and traceability for 300 common drug brands including analgesics, vitamins, diabetes and hypertension medicines etc. This step is aimed at preventing spurious drugs from getting into circulation.

The Union Ministry of Health has made necessary amendments to the Drugs Rules, 1945, to implement this. In March the ministry had asked the department of pharmaceuticals (DoP) to shortlist the 300 drug brands that can be included for implementation of mandatory QR codes. The National Pharmaceutical Pricing Authority (NPPA) had identified the list of 300 drugs which include widely used medicines like pain-killers, contraceptives, vitamins, blood-sugar and hypertension medicines, etc.

Popular brands like Dolo, Allegra, Asthalin, Augmentin, Saridon, Limcee, Calpol, Corex, Thyronorm, Unwanted 72 etc were identified. (see list) These high selling brands have been shortlisted based on their moving annual turnover (MAT) value.

According to reports, the has suspended three scientists associated with Central Drugs Laboratory, Kolkata, India’s apex lab, responsible for conducting quality checks on drugs and vaccines in relation to fake remdesivir sales. These scientists submitted their report to the CDSCO after the batch of remdesivir drugs expired. An investigation by the had revealed that the sample of remdesivir was spurious, and thus the three accused were trying to conceal that in their quality report to the CDSCO.

Interestingly, remdesivir does not feature in the list of 300 brands that would bear QR codes.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Source link


Please enter your comment!
Please enter your name here